

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918
FAX : 022-2493 0534 / 2493 9633
e-mail : info@jbcpl.com
Website : www.jbcpl.com
CIN : L24390MH1976PLC019380

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30/09/2015

Sl.No.	PART I - Particulars	Quarter ended			Half Year		(Rs. in lakhs)
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	31/03/2015
1	Income from Operations						
	a. Net sales (Net of excise duty)	28,070.95	27,914.93	27,486.10	55,985.88	53,157.31	1,03,813.61
	b. Other Operating Income	607.15	505.92	539.67	1,113.07	1,128.74	2,328.51
	Total Income from Operations (Net) (a+b)	28,678.10	28,420.85	28,025.77	57,098.95	54,286.05	1,06,142.12
2	Expenses						
	a. Cost of materials consumed	9,819.75	9,022.98	8,703.83	18,842.73	17,042.47	34,158.73
	b. Purchases of stock-in-trade	2,003.69	2,309.10	3,070.88	4,312.79	5,472.91	9,009.66
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(189.50)	599.54	(507.40)	410.04	(69.94)	(68.24)
	d. Employees benefits expense	4,033.19	4,097.01	3,553.23	8,130.20	7,271.50	14,681.81
	e. Depreciation and amortization expense	1,004.00	977.00	1,001.00	1,981.00	1,991.00	3,759.99
	f. Exchange Fluctuation Transactional (Gain)/Loss	86.78	118.72	25.97	205.50	(23.48)	58.16
	g. Other Expenses	7,556.39	7,320.63	7,422.79	14,877.02	14,000.81	28,633.60
	Total Expenses	24,314.30	24,444.98	23,270.30	48,759.28	45,685.27	90,233.71
3	Profit from Operations before Other Income, Finance Cost (1-2)	4,363.80	3,975.87	4,755.47	8,339.67	8,600.78	15,908.41
4	Other Income	2,651.63	429.71	520.52	3,081.34	694.48	1,040.88
5	Profit before Finance Cost (3+4)	7,015.43	4,405.58	5,275.99	11,421.01	9,295.26	16,949.29
6	Finance Cost	308.41	171.03	225.40	479.44	357.97	665.01
7	Profit after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	6,707.02	4,234.55	5,050.59	10,941.57	8,937.29	16,284.28
8	Exchange Fluctuation Translation Gain / (Loss)	(478.49)	398.64	(782.29)	(79.85)	(413.52)	(373.86)
9	Profit before Tax (7+-8)	6,228.53	4,633.19	4,268.30	10,861.72	8,523.77	15,910.42
10	Tax expenses	1,330.00	1,205.00	1,079.57	2,535.00	2,155.94	4,552.17
11	Net Profit/(Loss) after Tax (9-10)	4,898.53	3,428.19	3,188.72	8,326.72	6,367.83	11,358.25
12	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.16	1,696.16	1,696.40	1,696.16	1,696.16
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	99,934.99
14	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	5.78	4.04	3.76	9.82	7.51	13.40
	(2) Diluted	5.78	4.04	3.76	9.82	7.51	13.39

Sl. No.	PART II - Particulars	Quarter ended			Half Year		Year ended
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	3,75,14,638	3,75,02,888	3,75,01,697	3,75,14,638	3,75,01,697	3,75,02,888
	- Percentage of shareholding	44.23	44.22	44.22	44.23	44.22	44.22
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	4,73,05,337	4,73,05,337	4,73,06,528	4,73,05,337	4,73,06,528	4,73,05,337
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.77	55.78	55.78	55.77	55.78	55.78

Unique



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR..
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/09/2015
Pending at the beginning of the quarter	0
Received during the quarter	9
Disposed of during the quarter	9
Remaining unresolved at the end of the quarter	0

NOTES

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on November 4, 2015.
2. The statutory auditors have carried out limited review of the above financial results for the quarter ended on September 30, 2015.
3. The increase in other income represents gain on sale/ redemption of investments.
4. The company is engaged in a single segment of activity viz. Pharmaceuticals.
5. The statement of assets and liabilities as of September 30, 2015 is as under:

		(Rs. in lakhs)	
Particulars		AS AT 30/09/2015	AS AT 31/03/2015
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	a. Share Capital	1,696.40	1,696.16
	b. Reserves and surplus	1,08,270.82	99,934.99
	Sub Total of Shareholders' funds	1,09,967.22	1,01,631.15
2	Non-current liabilities		
	a. Long-term borrowings	-	40.00
	b. Deferred tax liabilities (Net)	2,247.22	2,162.22
	c. Long-term provisions	1,341.58	1,202.60
	Sub-Total - Non-current liabilities	3,588.80	3,404.82
3	Current liabilities		
	a. Short-term borrowings	14,172.95	10,472.97
	b. Trade payables	6,037.85	6,230.76
	c. Other current liabilities	10,016.62	8,259.92
	d. Short-term provisions	647.19	14,876.41
	Sub-Total - Current liabilities	30,874.61	39,840.06
	TOTAL-EQUITY AND LIABILITIES	1,44,430.63	1,44,876.03
B	ASSETS		
1	Non-current assets		
	a. Fixed assets	44,966.19	35,604.09
	b. Non-current investments	23,071.57	23,071.57
	c. Long-term loans and advances	1,637.02	1,201.91
	Sub-Total - Non-current assets	69,674.78	59,877.57
2	Current assets		
	a. Current investments	23,925.22	36,678.17
	b. Inventories	12,328.41	12,847.40
	c. Trade receivables	28,522.12	24,849.05
	d. Cash and cash equivalents	629.60	905.52
	e. Short-term loans and advances	9,350.50	9,718.32
	f. Other current assets	-	-
	Sub-Total - Current assets	74,755.85	84,998.46
	TOTAL-ASSETS	1,44,430.63	1,44,876.03

The previous quarter's/period's figures have been regrouped/re-stated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.


J.B. Mody
Chairman & Managing Director

Place : Mumbai

Date : November 4, 2015



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
 "NEELAM CENTRE", 'B' WING, 4TH FLR.,
 HIND CYCLE ROAD, WORLI,
 MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918
 FAX : 022-2493 0534 / 2493 9633
 e-mail : info@jbcpl.com
 Website : www.jbcpl.com
 CIN : L24390MH1976PLC019380

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, November 4, 2015

Unaudited Financial Results for Q 2- 2015-16

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on September 30, 2015. The highlights of Y-o-Y results are as under:

Particulars	(Rs. in crores)	
	Q2-2015-16	Q2-2014-15
Net Sales	280.71	274.86
Other Operating income	6.07	5.40
Other Income	26.52	5.20
Total Income	313.30	285.46
EBIDTA	75.41	54.95
Operating Profit	38.85	39.73
Profit before tax	62.29	42.68
Profit after tax	48.99	31.89
EPS (Rs.) (FV 2)	5.78	3.76

The net sales for the quarter at Rs. 280.71 crores were marginally higher against net sales in the corresponding quarter in the previous year. The growth in top line was impacted due to overall lower exports. The PBT and PAT for the quarter at Rs. 62.29 crores and Rs. 48.99 crores were 45.93% and 53.62% higher respectively over corresponding quarter in the previous year.

The domestic formulations business at sales of Rs. 108.18 crores registered growth of 11.06%, while the focus products group achieved growth of 17%. The focus on cardiovascular products and topical preparations to drive the growth for the division during the year has met with good success. The contrast media products sales in domestic market at sales of Rs. 10.87 crores registered growth of 22.43%.

The overall formulations exports at Rs. 133.03 crores registered growth of 3.06% during the quarter. While the exports for Russia-CIS markets at Rs. 16.78 crores grew by 35.14%, the exports to Rest of the world markets at Rs. 88.63 crores were lower due to lower demand and uncertainty in many markets largely due to depreciation of local currency against US \$.



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

The API sales at Rs. 22.21 crores were lower. The product development income and other sales income during the quarter amounted to Rs. 6.42 crores.

Acquisition:

With a view to consolidate control and expand business in African continent, the board of directors has today also approved acquisition of 21,94,030 (51%) ordinary shares in Biotech Laboratories (Pty.) Ltd., South Africa ("Biotech"), held by Africa Biopharma Investments (Pty.) Ltd. by a company's subsidiary, subject to necessary approvals and definitive agreements to be entered into with the seller.

The company's subsidiary J.B. Healthcare Pvt. Ltd. presently holds 21,07,990 (49%) ordinary shares in Biotech, besides 175,591 Non-Redeemable Convertible Preference Shares. Post the proposed acquisition, conversion of preference shares and certain fresh issuance of ordinary shares by Biotech, the shareholding of the company's subsidiaries in Biotech will increase to over 95%.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of DMFs and ANDAs. Its State-of-the-Art manufacturing facilities are approved by health authorities of regulated markets.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary and Vice President- Compliance
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 2482 2311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.